United States

AFFO (TTM)

AFFO/share (TTM)

AFFO/share Guidance

AFFO (Quarter)

AFFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/AFFO

Size (ft²)

Occupancy

The Company is a fully integrated REIT primarily focused on the ownership, acquisition, development and management of
retail properties net leased to industry leading tenants.

Agree Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, ADC is classified as investment grade

Period: 2022 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2022 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's Adjusted FFO

Adjusted FFO Growth

Assessment of recent increases in Adjusted FFO per share, indicating profitability

Adjusted FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LAUSANNE, Switzerland , Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 127,000 of the Company's common shares to three new employees on August 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter ended June 30, 2025. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. Second Quarter 2025 Financial and Operating Highlights: Invested approximately $350 million in 110 retail net lease properties across all three external growth platforms Net Income per share attributable to common stockholders decreased 18.5% to $.

Agree Realty Corporation Reports Second Quarter 2025 Results

Shares of Realty Income (NYSE:O) gained 0.86% over the past month, bringing its year-to-date gain to 9.45%. In addition to outperforming the S&amp;P 500&#8217;s gain of 8.61% in 2025, O has provided shareholders with a dividend currently yielding 5.60%. Realty Income remains a staple in dividend investors&#8217; portfolios. The commercial REIT dividend — which pays out monthly and has for 659 consecutive months — is a large reason investors are confident in the stock moving forward. Another reason: its expanding footprint in the European market that has seen commercial properties with long-term net lease agreements added to its +13,000-property portfolio in the U.K., Spain and other countries. Billing itself &#8220;The Monthly Dividend Company,&#8221; the real estate investment trust (REIT) blazed a new path in the field that numerous other REITs now follow. The track record of payments for O is remarkable, and since being listed on the NYSE in 1994, the REIT has increased its dividend every quarter. Having raised the payout for 30 consecutive years, Realty Income is now a Dividend Aristocrat, or a stock that is part of the S&amp;P 500 and has increased its dividend for 25 consecutive years or more. Since its IPO in 1994, Realty Income has provided investors with a 589.46% return, not including reinvested dividends. The question is, where does Realty Income stock go from here. 24/7 Wall St. offers readers insights into our assumptions about the stock’s prospects, what sort of growth we see in O stock for the next several years, and our best estimates for Reality Income stock price each year through 2030. Realty Income (O) Recent Stock Performance Here’s a table summarizing the performance in share price, revenues, and adjusted funds from operations (AFFO) of O stock from 2019 to 2024: Year Stock Price Revenue* Adjusted Funds From Operations (AFFO)* 2019 $71.30 $1.488 $1.050 2020 $60.20 $1.647 $1.172 2021 $71.59 $2.080 $1.488 2022 $63.43 $3.343 $2.401 2023 $57.42 $4.

Realty Income (NYSE: O) Stock Price Prediction and Forecast 2025-2030 (July 2025)

Annaly Capital (NLY 0.66%) has a huge dividend yield that approaches 15%. And the mortgage real estate investment trust (REIT) just increased its dividend at the start of 2025.

Prediction: 2 Stocks That Will Be Worth More Than Annaly Capital 5 Years From Now

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that Nature Medicine (IF: 58.7) has published the results of the Phase 1 clinical study of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma[Link]. Publication in this leading international academic journal indicates the strong recognition of the therapy's clinical potential and marks another significant milestone in China's progress in developing novel anti-tumor medications.

Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

TYSONS, Va.--(BUSINESS WIRE)--Alarm.com (Nasdaq: ALRM) announces the release of its latest Smart Thermostat—the ADC-T25. Building on the proven reliability of Alarm.com's suite of thermostats, the T25 is compatible with most common HVAC systems, offering the easiest installation yet, a streamlined design, and advanced sensing capabilities, all at a market-expanding, affordable price point. Designed by Building36 with easy installation in mind, the T25 has flexible wiring options that allow it t.

Alarm.com Launches the ADC-T25 Smart Thermostat: Advanced HVAC Control at an Accessible Price

Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that its highly impactful programs on ADC and Radiopharma programs, which includes collaborations and preclinical studies on cancer therapies with Accum® are ongoing. Defence's Accum®-based ADCs have demonstrated enhanced intracellular delivery and cytotoxic activity in multiple preclinical cancer models compared to conventional ADCs.

Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer

When you shift from building a nest egg to living off of your savings in retirement, there may also be a big change in the investment approach you take. Income often becomes more important since leaving the workforce means you need to replace the monthly income stream from your job.

3 Stocks That Cut You a Check Each Month

Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.

5 Monthly Pay High-Yield Passive Income Stocks Are Printing Money For Shareholders

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.256 per common share. The monthly dividend reflects an annualized dividend amount of $3.072 per common share, representing a 2.4% increase over the annualized dividend amount of $3.00 per common share from the third quarter of 2024. The dividend is payable August 14, 2025 to stockholders of.

Agree Realty Declares Monthly Common and Preferred Dividends

There are different ways to use dividends when it comes to selecting investments. Often, dividend investors focus all their attention on the highest-yielding stocks.

2 Top Dividend Stocks to Buy in July

HONG KONG , July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's first bispecific ADC to enter clinical trials.

Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy

LAUSANNE, Switzerland , July 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,000 of the Company's common shares to one new employee on July 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its second quarter 2025 operating results after the market closes on Thursday, July 31, 2025. A conference call to discuss the Company's operating results is scheduled for Friday, August 1, 2025 at 9:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (800) 715-9871   International (646) 307-1963  .

Agree Realty Announces Second Quarter 2025 Earnings Release Date and Conference Call Information

SAN FRANCISCO and SUZHOU, China , June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, held its Oncology R&D Day, unveiling its forward-looking strategy centered on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies. This strategic focus aims to redefine the standards of cancer treatment and propel Innovent toward becoming a global, premier biopharmaceutical leader.

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda® (pembrolizumab).

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

We have to consider that insiders buying their stock wouldn't put up their own money unless they believed the move would be profitable.

Five Popular Stocks Insiders Have Been Aggressively Buying

According to the Internal Revenue Service (IRS), passive income generally includes earnings from rental activity or any trade, business, or investment in which the individual does not materially participate.

5 Very Safe Dividend Stocks Can Provide a Lifetime of Monthly Passive Income

Using Realty Income's annualized dividend of $3.228, you could collect an easy $1,400 a year.

If You Want $8,030 in Annual Income, Invest $25,000 in Each of these Stocks Today

Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Retired investors who have shifted from building a nest egg to living off their accumulated savings often start to focus on dividend stocks. Going with monthly pay dividend stocks is almost like creating your own paycheck.

​​3 Stocks That Cut You a Check Each Month

Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69% CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment ZYNLONTA was generally well tolerated and safety was consistent with known profile LAUSANNE, Switzerland , June 16, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA® to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be presented during a poster session at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20. These data will be made available online beginning on Wednesday, June 18, at 8:30 a.m.

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

LAUSANNE, Switzerland , June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $100.0 million private investment in public equity ("PIPE") financing. In the PIPE, ADC Therapeutics is selling 13.0 million common shares at $3.53 per share and pre-funded warrants to purchase 15.7 million common shares at $3.43, per pre-funded warrant, which is the price per common share in the PIPE minus the exercise price of CHF 0.08 per pre-funded warrant.

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients 25 of 26 patients achieving CR remained in CR as of the data cut-off Initial data show the combination is generally well tolerated with a manageable safety profile Company expanding enrollment for LOTIS-7 to 100 patients at 150 µg/kg dose Company to host conference call today at 8:00 a.m. ET/2:00 p.m.

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

ROYAL OAK, Mich. , June 10, 2025 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.256 per common share.

Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its U.S. patent application covering one of its next-generation antibody-drug conjugate (ADC) technologies. The allowance of U.S. patent application no.

Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology

Investing in real estate can be a great way to make passive income. There are lots of options, including buying a rental property.

3 Top Real Estate Dividend Stocks to Buy for Super Easy Passive Income in June

SAN FRANCISCO and SUZHOU, China , June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, updated the clinical data of IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) in advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors.

2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors

SAN FRANCISCO and SUZHOU, China , June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, updated the Phase 1 study results of IBI343, a novel anti-CLDN18.2 ADC, for the treatment of advanced pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. With extended follow-up and more mature data on progression-free survival (PFS) and overall survival (OS), IBI343 has demonstrated promising therapeutic efficacy in patients with CLDN18.2-positive advanced pancreatic cancer.

ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer

LAUSANNE, Switzerland , June 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 107,550 of the Company's common shares to two new employees on June 2, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity across dose and FRα expression levels in women with heavily pre-treated platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine. A preliminary overall objective response rate (ORR) of 55% was observed at the potential recommended Phase 2 dose of 4 mg/kg.

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating zocilurtatug pelitecan, or ZL-1310, the Company's potential first-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for patients with extensive-stage small cell lung cancer (ES-SCLC), will be presented today during a poster session at the 2025 American Society of Clinical Oncology (AS.

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

The S&P 500 (^GSPC -0.01%) is offering a tiny 1.3% yield today. The average real estate investment trust (REIT) has a yield of around 4.1%.

Best Stock to Buy Right Now: Realty Income vs. Agree Realty

LAUSANNE, SWITZERLAND , AUG. 1, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE GRANTS OF OPTIONS TO PURCHASE AN AGGREGATE OF 127,000 OF THE COMPANY'S COMMON SHARES TO THREE NEW EMPLOYEES ON AUGUST 1, 2025 (EACH, A "GRANT"). THE GRANTS WERE OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEES' EMPLOYMENT.

ADC THERAPEUTICS MAKES GRANTS TO NEW EMPLOYEES UNDER INDUCEMENT PLAN

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED RESULTS FOR THE QUARTER ENDED JUNE 30, 2025. ALL PER SHARE AMOUNTS INCLUDED HEREIN ARE ON A DILUTED PER COMMON SHARE BASIS UNLESS OTHERWISE STATED. SECOND QUARTER 2025 FINANCIAL AND OPERATING HIGHLIGHTS: INVESTED APPROXIMATELY $350 MILLION IN 110 RETAIL NET LEASE PROPERTIES ACROSS ALL THREE EXTERNAL GROWTH PLATFORMS NET INCOME PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS DECREASED 18.5% TO $.

AGREE REALTY CORPORATION REPORTS SECOND QUARTER 2025 RESULTS

SAN FRANCISCOAND SUZHOU,CHINA, JULY 16, 2025 /PRNEWSWIRE/ -- INNOVENT BIOLOGICS, INC. ("INNOVENT") (HKEX: 01801), A WORLD-CLASS BIOPHARMACEUTICAL COMPANY THAT DEVELOPS, MANUFACTURES AND COMMERCIALIZES HIGH-QUALITY MEDICINES FOR THE TREATMENT OF ONCOLOGY, CARDIOVASCULAR AND METABOLIC, AUTOIMMUNE, OPHTHALMOLOGY AND OTHER MAJOR DISEASES, ANNOUNCED THAT NATURE MEDICINE (IF: 58.7) HAS PUBLISHED THE RESULTS OF THE PHASE 1 CLINICAL STUDY OF IBI343, AN INNOVATIVE ANTI-CLDN18.2 ADC, FOR THE TREATMENT OF ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION (G/GEJ) ADENOCARCINOMA[LINK]. PUBLICATION IN THIS LEADING INTERNATIONAL ACADEMIC JOURNAL INDICATES THE STRONG RECOGNITION OF THE THERAPY'S CLINICAL POTENTIAL AND MARKS ANOTHER SIGNIFICANT MILESTONE IN CHINA'S PROGRESS IN DEVELOPING NOVEL ANTI-TUMOR MEDICATIONS.

NATURE MEDICINE PUBLISHED PHASE 1 RESULTS OF INNOVENT BIOLOGICS' ANTI-CLDN18.2 ADC (IBI343) IN PATIENTS WITH ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

TYSONS, VA.--(BUSINESS WIRE)--ALARM.COM (NASDAQ: ALRM) ANNOUNCES THE RELEASE OF ITS LATEST SMART THERMOSTATTHE ADC-T25. BUILDING ON THE PROVEN RELIABILITY OF ALARM.COM'S SUITE OF THERMOSTATS, THE T25 IS COMPATIBLE WITH MOST COMMON HVAC SYSTEMS, OFFERING THE EASIEST INSTALLATION YET, A STREAMLINED DESIGN, AND ADVANCED SENSING CAPABILITIES, ALL AT A MARKET-EXPANDING, AFFORDABLE PRICE POINT. DESIGNED BY BUILDING36 WITH EASY INSTALLATION IN MIND, THE T25 HAS FLEXIBLE WIRING OPTIONS THAT ALLOW IT T.

ALARM.COM LAUNCHES THE ADC-T25 SMART THERMOSTAT: ADVANCED HVAC CONTROL AT AN ACCESSIBLE PRICE

MONTREAL, QUEBEC--(NEWSFILE CORP. - JULY 14, 2025) - DEFENCE THERAPEUTICS INC.(CSE: DTC) (OTCQB: DTCFF) (FSE: DTC)("DEFENCE" OR THE "COMPANY"), A LEADING BIOTECHNOLOGY COMPANY SPECIALIZING IN DRUG DELIVERY TECHNOLOGIES, IS PLEASED TO ANNOUNCE THAT ITS HIGHLY IMPACTFUL PROGRAMS ON ADC AND RADIOPHARMA PROGRAMS, WHICH INCLUDES COLLABORATIONS AND PRECLINICAL STUDIES ON CANCER THERAPIES WITH ACCUM ARE ONGOING. DEFENCE'S ACCUM-BASED ADCS HAVE DEMONSTRATED ENHANCED INTRACELLULAR DELIVERY AND CYTOTOXIC ACTIVITY IN MULTIPLE PRECLINICAL CANCER MODELS COMPARED TO CONVENTIONAL ADCS.

DEFENCE'S ACCUM TECHNOLOGY WITH ADC AND RADIOPHARMACEUTICAL PROGRAMS TARGET CANCER

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.256 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.072 PER COMMON SHARE, REPRESENTING A 2.4% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.00 PER COMMON SHARE FROM THE THIRD QUARTER OF 2024. THE DIVIDEND IS PAYABLE AUGUST 14, 2025 TO STOCKHOLDERS OF.

AGREE REALTY DECLARES MONTHLY COMMON AND PREFERRED DIVIDENDS

HONG KONG , JULY 3, 2025 /PRNEWSWIRE/ -- AKESO, INC. (9926.HK) ("AKESO" OR THE "COMPANY") HAS ANNOUNCED THE SUCCESSFUL ENROLLMENT OF THE FIRST PATIENT IN ITS PHASE IA CLINICAL TRIAL FOR AK146D1, A BISPECIFIC ANTIBODY-DRUG CONJUGATE (ADC) TARGETING TROP2 AND NECTIN4. AK146D1 IS AKESO'S FIRST BISPECIFIC ADC TO ENTER CLINICAL TRIALS.

AKESO'S FIRST BISPECIFIC ADC (TROP2/NECTIN4 ADC) ENTERS CLINICAL TRIALS, STRENGTHENING LEADERSHIP IN 'IO+ADC' 2.0 STRATEGY

LAUSANNE, SWITZERLAND , JULY 1, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE GRANTS OF OPTIONS TO PURCHASE AN AGGREGATE OF 17,000 OF THE COMPANY'S COMMON SHARES TO ONE NEW EMPLOYEE ON JULY 1, 2025 (EACH, A "GRANT"). THE GRANTS WERE OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEES' EMPLOYMENT.

ADC THERAPEUTICS MAKES GRANT TO NEW EMPLOYEE UNDER INDUCEMENT PLAN

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT IT WILL RELEASE ITS SECOND QUARTER 2025 OPERATING RESULTS AFTER THE MARKET CLOSES ON THURSDAY, JULY 31, 2025. A CONFERENCE CALL TO DISCUSS THE COMPANY'S OPERATING RESULTS IS SCHEDULED FOR FRIDAY, AUGUST 1, 2025 AT 9:00 AM ET. INTERESTED PARTIES AND SHAREHOLDERS MAY ACCESS THE CALL VIA TELECONFERENCE OR WEBCAST: TELECONFERENCE: USA TOLL FREE (800) 715-9871  INTERNATIONAL (646) 307-1963 .

AGREE REALTY ANNOUNCES SECOND QUARTER 2025 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION

SAN FRANCISCO AND SUZHOU, CHINA , JUNE 30, 2025 /PRNEWSWIRE/ -- INNOVENT BIOLOGICS, INC. ("INNOVENT") (HKEX: 01801), A WORLD-CLASS BIOPHARMACEUTICAL COMPANY THAT DEVELOPS, MANUFACTURES, AND COMMERCIALIZES HIGH-QUALITY MEDICINES FOR THE TREATMENT OF ONCOLOGY, AUTOIMMUNE, CARDIOVASCULAR AND METABOLIC, OPHTHALMOLOGY, AND OTHER MAJOR DISEASES, HELD ITS ONCOLOGY R&D DAY, UNVEILING ITS FORWARD-LOOKING STRATEGY CENTERED ON DUAL INNOVATION IN NEXT-GENERATION IMMUNO-ONCOLOGY (IO) AND ANTIBODY-DRUG CONJUGATE (ADC) TECHNOLOGIES. THIS STRATEGIC FOCUS AIMS TO REDEFINE THE STANDARDS OF CANCER TREATMENT AND PROPEL INNOVENT TOWARD BECOMING A GLOBAL, PREMIER BIOPHARMACEUTICAL LEADER.

INNOVENT BIOLOGICS SHOWCASES "DUAL INNOVATIONS" AT ONCOLOGY R&D DAY, PIONEERING THE FUTURE OF CANCER TREATMENT WITH NEXT-GENERATION IO AND ADC PLATFORMS

NORWOOD, MASS., JUNE 25, 2025 (GLOBE NEWSWIRE) -- CORBUS PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: CRBP) (CORBUS OR THE COMPANY), A CLINICAL-STAGE COMPANY FOCUSED ON ONCOLOGY AND OBESITY, TODAY ANNOUNCED THE DOSING OF THE FIRST PARTICIPANT IN THE PD-1 COMBINATION ARM OF ITS PHASE 1 STUDY INVESTIGATING CRB-701 IN SOLID TUMORS (THE PHASE 1 WESTERN STUDY). PARTICIPANTS IN THIS ARM OF THE STUDY ARE BEING RANDOMIZED TO THE 2.7 MG/KG AND 3.6 MG/KG COHORTS IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB).

CORBUS PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED WITH ITS NECTIN-4 TARGETING ADC CRB-701 IN COMBINATION WITH PEMBROLIZUMAB

DIFFERENTIATED PH1 PAYLOAD IS A SPLICEOSOME INHIBITOR DESIGNED TO INHIBIT RNA SPLICING, LEADING TO CANCER CELL DEATH AND ACTIVATION OF IMMUNE SYSTEM THROUGH MULTIPLE MECHANISMS

AKARI THERAPEUTICS BOLSTERS GLOBAL IP ESTATE FOR ITS NOVEL ANTIBODY DRUG CONJUGATE (ADC) IMMUNO-ONCOLOGY PAYLOAD, PH1, WITH RECENT GRANTING OF PATENT PROTECTION ACROSS INDIA

UPDATED PHASE 2 DATA EVALUATING ZYNLONTA AS A MONOTHERAPY DEMONSTRATE OVERALL RESPONSE RATE (ORR) OF 85% AND COMPLETE RESPONSE (CR) RATE OF 69% CR MAINTAINED IN 17 OF 18 PATIENTS WHO ACHIEVED CR, WITH LONGEST DURATION OF CR OF 27 MONTHS FROM START OF TREATMENT ZYNLONTA WAS GENERALLY WELL TOLERATED AND SAFETY WAS CONSISTENT WITH KNOWN PROFILE LAUSANNE, SWITZERLAND , JUNE 16, 2025 /PRNEWSWIRE/ --ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED UPDATED DATAFROM A PHASE 2 MULTICENTER INVESTIGATOR-INITIATED TRIAL (IIT) OF ZYNLONTA TO TREAT RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL) WILL BE PRESENTED DURING A POSTER SESSION AT THE 18TH INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (ICML) IN LUGANO, SWITZERLAND ON FRIDAY, JUNE 20. THESE DATA WILL BE MADE AVAILABLE ONLINE BEGINNING ON WEDNESDAY, JUNE 18,AT 8:30 A.M.

ADC THERAPEUTICS ANNOUNCES UPDATED ZYNLONTA INVESTIGATOR-INITIATED TRIAL DATA IN R/R MARGINAL ZONE LYMPHOMA PRESENTED AT 18TH INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (ICML)

LAUSANNE, SWITZERLAND , JUNE 12, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT IT HAS ENTERED INTO SECURITIES PURCHASE AGREEMENTS FOR THE SALE OF ITS EQUITY SECURITIES TO CERTAIN INSTITUTIONAL INVESTORS IN A $100.0 MILLION PRIVATE INVESTMENT IN PUBLIC EQUITY ("PIPE") FINANCING. IN THE PIPE, ADC THERAPEUTICS IS SELLING 13.0 MILLION COMMON SHARES AT $3.53 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE 15.7 MILLION COMMON SHARES AT $3.43, PER PRE-FUNDED WARRANT, WHICH IS THE PRICE PER COMMON SHARE IN THE PIPE MINUS THE EXERCISE PRICE OF CHF 0.08 PER PRE-FUNDED WARRANT.

ADC THERAPEUTICS ANNOUNCES $100 MILLION PRIVATE PLACEMENT EXTENDING EXPECTED CASH RUNWAY INTO 2028

ZYNLONTA IN COMBINATION WITH GLOFITAMAB (COLUMVI) IN PATIENTS WITH R/R DLBCL DEMONSTRATED CLINICALLY MEANINGFUL BENEFIT WITH OVERALL RESPONSE RATE (ORR) OF 93.3% AND A COMPLETE RESPONSE (CR) RATE OF 86.7% ACROSS 30 EFFICACY EVALUABLE PATIENTS 25 OF 26 PATIENTS ACHIEVING CR REMAINED IN CR AS OF THE DATA CUT-OFF INITIAL DATA SHOW THE COMBINATION IS GENERALLY WELL TOLERATED WITH A MANAGEABLE SAFETY PROFILE COMPANY EXPANDING ENROLLMENT FOR LOTIS-7 TO 100 PATIENTS AT 150 G/KG DOSE COMPANY TO HOST CONFERENCE CALL TODAY AT 8:00 A.M. ET/2:00 P.M.

ADC THERAPEUTICS ANNOUNCES UPDATED DATA FROM LOTIS-7 CLINICAL TRIAL PRESENTED AT THE EUROPEAN HEMATOLOGY ASSOCIATION 2025 CONGRESS

ROYAL OAK, MICH. , JUNE 10, 2025 /PRNEWSWIRE/ -- AGREE REALTY CORPORATION (NYSE: ADC) (THE "COMPANY") TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.256 PER COMMON SHARE.

MONTREAL, QUEBEC--(NEWSFILE CORP. - JUNE 9, 2025) - DEFENCE THERAPEUTICS INC.(CSE: DTC) (OTCQB: DTCFF) (FSE: DTC)("DEFENCE" OR THE "COMPANY"), A LEADING BIOTECHNOLOGY COMPANY SPECIALIZING IN DRUG DELIVERY TECHNOLOGIES, IS PLEASED TO ANNOUNCE THAT THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) HAS ISSUED A NOTICE OF ALLOWANCE FOR ITS U.S. PATENT APPLICATION COVERING ONE OF ITS NEXT-GENERATION ANTIBODY-DRUG CONJUGATE (ADC) TECHNOLOGIES. THE ALLOWANCE OF U.S. PATENT APPLICATION NO.

DEFENCE THERAPEUTICS RECEIVES USPTO ALLOWANCE FOR PATENT APPLICATION COVERING NEXT-GEN ADC TECHNOLOGY

SAN FRANCISCO AND SUZHOU, CHINA , JUNE 2, 2025 /PRNEWSWIRE/ --INNOVENT BIOLOGICS, INC. ("INNOVENT") (HKEX: 01801), A WORLD-CLASS BIOPHARMACEUTICAL COMPANY THAT DEVELOPS, MANUFACTURES AND COMMERCIALIZES HIGH-QUALITY MEDICINES FOR THE TREATMENT OF ONCOLOGY, CARDIOVASCULAR AND METABOLIC, AUTOIMMUNE, OPHTHALMOLOGY AND OTHER MAJOR DISEASES,UPDATED THE PHASE 1 STUDY RESULTS OF IBI343, A NOVEL ANTI-CLDN18.2 ADC, FOR THE TREATMENT OF ADVANCED PANCREATIC CANCER AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING. WITH EXTENDED FOLLOW-UP AND MORE MATURE DATA ON PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS), IBI343 HAS DEMONSTRATED PROMISING THERAPEUTIC EFFICACY IN PATIENTS WITH CLDN18.2-POSITIVE ADVANCED PANCREATIC CANCER.

ASCO 2025 ORAL PRESENTATION: INNOVENT BIOLOGICS ANNOUNCES UPDATED DATA OF IBI343 (NOVEL ANTI-CLDN18.2 ADC) FROM THE PHASE 1 CLINICAL STUDY IN PATIENTS WITH ADVANCED PANCREATIC CANCER

SAN FRANCISCO ANDSUZHOU, CHINA , JUNE 2, 2025 /PRNEWSWIRE/ --INNOVENT BIOLOGICS, INC. ("INNOVENT") (HKEX: 01801), A WORLD-CLASS BIOPHARMACEUTICAL COMPANY THAT DEVELOPS, MANUFACTURES AND COMMERCIALIZES HIGH-QUALITY MEDICINES FOR THE TREATMENT OF ONCOLOGIC, AUTOIMMUNE, CARDIOVASCULAR AND METABOLIC, OPHTHALMOLOGIC AND OTHER MAJOR DISEASES, UPDATED THE CLINICAL DATA OF IBI354 (HER2 MONOCLONAL ANTIBODY-CAMPTOTHECIN DERIVATIVE CONJUGATE) IN ADVANCED SOLID TUMORS AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING. IBI354 HAS DEMONSTRATED PROMISING ANTI-TUMOR EFFICACY AND FAVORABLE SAFETY PROFILES ACROSS MULTIPLE SOLID TUMORS.

2025 ASCO PRESENTATION: INNOVENT BIOLOGICS ANNOUNCES UPDATED DATA OF IBI354 (NOVEL ANTI-HER2 ADC) FROM THE PHASE 1/2 CLINICAL STUDY IN ADVANCED OVARIAN CANCER, BREAST CANCER AND OTHER SOLID TUMORS

LAUSANNE, SWITZERLAND , JUNE 2, 2025 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE GRANTS OF OPTIONS TO PURCHASE AN AGGREGATE OF 107,550 OF THE COMPANY'S COMMON SHARES TO TWO NEW EMPLOYEES ON JUNE 2, 2025 (EACH, A "GRANT"). THE GRANTS WERE OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEES' EMPLOYMENT.

SHANGHAI & CAMBRIDGE, MASS.--(BUSINESS WIRE)--ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED THAT UPDATED DATA FROM AN ONGOING, GLOBAL PHASE 1A/1B CLINICAL TRIAL (NCT06179069) EVALUATING ZOCILURTATUG PELITECAN, OR ZL-1310, THE COMPANY'S POTENTIAL FIRST-IN-CLASS, DELTA-LIKE LIGAND (DLL3) ANTIBODY-DRUG CONJUGATE (ADC) FOR PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC), WILL BE PRESENTED TODAY DURING A POSTER SESSION AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (AS.

ZAI LAB PRESENTS POSITIVE PHASE 1 DATA FOR ZL-1310, A DLL3-TARGETED ADC, DEMONSTRATING ROBUST ANTI-TUMOR ACTIVITY AND SAFETY IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER AT 2025 ASCO ANNUAL MEETING

Agree Realty

ADC

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC